Table 3.

Patient and rheumatologist DCE results

Attribute	Level	Patients (n = 137)			Rheumatologists (n = 90)
		Partial utility	SE	p value*	Partial utility	SE	p value*
Time with optimal QoL	1 year	0.244	0.036	< 0.001	0.195	0.045	< 0.001
	10 years	2.44			1.951
	7 years	1.708			1.366
	5 years	1.22			0.976
	2 years	0.488			0.39
Substantial improvement of RA symptoms	1% patientsa	0.003	0.003	0.251	0.015	0.004	< 0.001
	9 out of 10 patients (90%)	0.303			1.35
	7 out of 10 patients (70%)	0.235			1.023
	5 out of 10 patients (50%)	0.168			0.731
	3 out of 10 patients (30%)	0.101			0.438
Onset of treatment action	7 days (ref)	0.000	–	–	0.000	–	–
	15 days	− 0.372	0.285	0.193	− 0.602	0.356	0.091
	1 month	− 0.562	0.255	0.027	− 1.083	0.326	0.001
	3 months	0.194	0.275	0.481	− 0.715	0.342	0.036
Severe adverse events	1% patientsa	− 0.156	0.058	0.007	− 0.182	0.074	0.014
	1 out of 100 patients (1%)	− 0.156			− 0.182
	5 out of 100 patients (5%)	− 0.781			− 0.908
Mild adverse events	1% patientsa	0.003	0.014	0.856	− 0.014	0.018	0.444
	10 out of 100 patients (10%)	0.025			− 0.139
	30 out of 100 patients (30%)	0.076			– 0.416
Mode of administration	Daily Oral (ref)	0.000	–	–	0.000	–	–
	Weekly subcutaneous	− 1.394	0.372	< 0.001	− 1.683	0.461	< 0.001
	Monthly subcutaneous	− 0.375	0.364	0.302	− 0.249	0.442	0.574
	Monthly intravenous	− 0.956	0.366	0.009	–  0.446	0.458	0.331
Additional cost/month for treatment	Additional 1€/month	− 0.012	0.007	0.102	– 0.009	0.009	0.296
	0	0			0
	10	− 0.119			–  0.092
	20	− 0.238			− 0.185
	50	− 0.594			− 0.462

Bold values indicate that there is statistical significance (p < 0.05)

QoL quality of life, RA rheumatoid arthritis, SE standard error

^aRefers to a 1% of increase of the proportion of patients